Hachfeld, AnnaAnnaHachfeldAtkinson, AndrewAndrewAtkinsonStute, PetraPetraStuteCalmy, AACalmyTarr, P EP ETarrDarling, K E AK E ADarlingBabouee Flury, BBBabouee FluryPolli, CCPolliSultan-Beyer, LLSultan-BeyerAbela, I AI AAbelaAebi-Popp, Karoline LieselotteKaroline LieselotteAebi-Popp2024-10-142024-10-142023-04-15https://boris-portal.unibe.ch/handle/20.500.12422/116830BACKGROUND Increasing numbers of women living with HIV transition through menopause. It is unclear if this transition has an impact on treatment adherence, viral suppression, psychiatric comorbidities or drug use. We aimed at examining adherence and viral suppression during the perimenopausal period and explored the influence of psychiatric comorbidities and active injection drug use (IDU). SETTING Retrospective Swiss HIV Cohort Study analysis from 01/2010 to 12/2018. METHODS We explored peri- and postmenopausal trends of viral blips, low-level viremia, viral failure, adherence, psychiatric comorbidities and IDU using interrupted time series (ITS) models. RESULTS Rates of depression and psychiatric care increased during perimenopause before decreasing afterwards. Negative treatment outcomes such as viral blips, low-level viremia, viral failure and low adherence steadily declined while transitioning through menopause - this was also true for subgroups of women with depression, psychiatric treatment and active IDU. CONCLUSIONS Increased rates of depression and psychiatric care while transitioning through menopause do not result in lower rates of adherence or viral suppression in women living with HIV in Switzerland.en600 - Technology::610 - Medicine & healtharticle10.48350/1767863659522610.1097/QAI.0000000000003158